bioAffinity Technologies, Inc.
BIAF
$-0.05
Change (1 day)
$3.62
Year High
$1.15
Year Low
Categories
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Revenue of bioAffinity Technologies, Inc. (BIAF)
Revenue in 2023 (TTM): $2.53 M
According to bioAffinity Technologies, Inc.'s latest financial reports the company's current revenue (TTM) is $2.53 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of bioAffinity Technologies, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.53 M | $542.02 K | $-7,723,640 | $-7,916,018 | $-7,937,011 |
| 2022 | $4.8 K | $4.34 K | $-5,821,090 | $-8,151,654 | $-8,154,113 |
| 2021 | $ | $-4,817 | $-1,476,653 | $-6,324,463 | $-6,326,413 |
| 2020 | $ | $-22,242 | $-6,861,574 | $-7,265,987 | $-7,268,737 |
| 2019 | $ | $-40,278 | $-3,051,960 | $-3,304,299 | $-3,307,499 |